wikipedia | Gain of function research (GoFR) is a field of medical research focused on the serial passaging of microorganisms in vitro and in vivo. This places positive selective pressure on the microorganisms to effect mutations that would increase their pathogenicity, transmissibility, and antigenicity. These studies can also expand the host tropism of a pathogen to new host species or organ tissue. This research reveals targets to better predict emerging infectious diseases and to develop vaccines and therapeutics.
In virology, gain-of-function research is employed to better understand current and future pandemics.[1] In vaccine development, gain-of-function research is conducted to gain a head start on a virus and to develop a vaccine or therapeutic before it emerges.[1]
In February 2000, a group at the Utrecht University led by Peter Rottier published a paper on their gain-of-function studies titled "Retargeting of Coronavirus by Substitution of the Spike Glycoprotein Ectodomain: Crossing the Host Cell Species Barrier" detailing how they constructed a mutant of the coronavirus mouse hepatitis virus, replacing the ectodomain of the spike glycoprotein (S) with the highly divergent ectodomain of the S protein of feline infectious peritonitis virus. According to the paper, "the resulting chimeric virus, designated fMHV, acquired the ability to infect feline cells and simultaneously lost the ability to infect murine cells in tissue culture".[2]
The World Health Organization in 2010 developed a "guidance document" for Dual Use Research of Concern (DURC) in the life sciences because "research that is intended [to] benefit, but which might easily be misapplied to do harm".[3]
In May 2012, a Japanese group of scientists operating out of the University of Wisconsin with funding from the Bill & Melinda Gates Foundation, ERATO, National Institute of Allergy and Infectious Diseases and support gifts from the National Institutes of Health and the Vietnamese National Institute of Hygiene and Epidemiology published a paper in the journal Nature about airborne transmission of the H5N1 bird flu introduced via respiratory droplet transmission from one ferret to another. The group "had altered the virus’s amino acid profile, allowing it to reproduce in mammal lungs, which are a bit colder than bird lungs. That small change allowed the virus to be transmitted via coughing and sneezing, and it solved the riddle of how H5N1 could become airborne in humans... (Some) members of Congress, among other critics around the world, responded to the publication of the research with alarm and condemnation." A New York Times editorial described the event as "An Engineered Doomsday."[4][5]
In May 2013, Hualan Chen, who was then director of the China's National Avian Influenza Reference Laboratory, and colleagues successfully created a new strain of influenza virus through a gain-of-function experiment at the BSL3 approved Harbin Veterinary Research Institute.[6] The Chinese scientists "deliberately mixed the H5N1 bird-flu virus, which is highly lethal [to birds] but not easily transmitted between [humans], with a 2009 strain of H1N1 flu virus, which is very infectious to humans."[7] This event caused consternation in European biotech circles, as Professor Simon Wain-Hobson of the Pasteur Institute the Chinese scientists "haven’t been thinking clearly about what they are doing. It’s very worrying... The virological basis of this work is not strong. It is of no use for vaccine development and the benefit in terms of surveillance for new flu viruses is oversold," while Lord May of Oxford said: "The record of containment in labs like this is not reassuring. They are taking it upon themselves to create human-to-human transmission of very dangerous viruses. It’s appallingly irresponsible."[7]
In May 2014, the Bundestag was presented a report written by the National Ethics Council on proposed guidance for governance of GoFR.[8] At the time, some in Germany were concerned over "GoFR pathogenic pandemic microbes raging out of control".[8] Epidemiologist Marc Lipsitch used "data of past biosafety breaches to calculate that" they occur with a probability "of 0.01 to 0.1 percent per lab per year."[8]
In October 2014, The White House under the Obama administration instituted a moratorium on gain-of-function research into influenza, MERS, and SARS, launched inquiries from the Office of Science and Technology Policy (OSTP); the National Science Advisory Board for Biosecurity (NSABB); and the symposia by National Research Council (NRC),[9] and paused funding for all projects for three years.[10][11][12][13] At least 18 GoFR projects were affected, "including work that had been continued ... in the labs of Fouchier and Kawaoka."[8]
In December 2014, Veronique Kiermer (at the time on the editorial board of Nature) discussed the considerations at her place of employment, that go into the publication of DURC. She came to the conclusion that "the journal's editorial and review boards should not (and could not) be the only gatekeepers who decide which research results should be published, either fully or redacted, 'because it is way too late in the process of GoFR.'"[8]
In December 2014, the National Research Council and the Institute of Medicine organized a two-day symposium to discuss the potential risks and benefits of Gain-of-Function Research. The event was attended by scientists from around the world, including George Gao, Gabriel Leung and Michael Selgelid, Baruch Fischhoff, Alta Charo, Harvey Fineberg, Jonathan Moreno, Ralph Cicerone, Margaret Hamburg, Jo Handelsman, Samuel Stanley, Kenneth Berns, Ralph Baric, Robert Lamb, Silja Vöneky, Keiji Fukuda, David Relman, and Marc Lipsitch.[14] One day later, the US government granted exceptions to the GoFR moratorium to seven out of 18 research projects that had been affected.[8]
In 2016, synthetic virology scientists and bioethics experts again raised concerns with the dual-use of gain-of-function research.[1][13]
By March 2016 the second symposium launched by the Obama administration reported that funding for gain-of-function research was provided by government agencies, pharmaceutical research companies, venture capital funds, colleges and universities, non-profit research institutions, foundations, and charities.[15]
In May 2016,[16] the NSABB published "Recommendations for the Evaluation and Oversight of Proposed Gain-of-Function Research".[17]
On 9 January 2017, the HHS published the "Recommended Policy Guidance for Departmental Development of Review Mechanisms for Potential Pandemic Pathogen Care and Oversight" (P3CO).[16]
On 19 December 2017 under the Trump administration, the NIH lifted the Obama moratorium into GoFR because it was deemed to be "important in helping us identify, understand, and develop strategies and effective countermeasures against rapidly evolving pathogens that pose a threat to public health,"[18] because on the same day the HHS P3CO Framework restored it.[19][18]
0 comments:
Post a Comment